After weight-loss surgery, the weight often creeps back. In a new analysis of Florida health records, GLP-1 drugs recovered about half of what had returned, without a rise in side effects.
The study was published August 25 in Obesity ↗ by Tarik Yuce, Rasha Radwan and colleagues at Purdue University, Indiana University and the University of Florida. It drew on the OneFlorida+ Data Trust, a large pool of electronic health records covering 2015 to 2024. The researchers pulled adults who had lost weight after metabolic and bariatric surgery and then regained at least 10 percent of it. Some of those patients later started a GLP-1 receptor agonist, the drug class that includes semaglutide, liraglutide and the dual GLP-1 plus GIP agent tirzepatide. Each new user was matched to non-users on body mass index and on the timing of their clinic visit, and the analysis was reweighted to blunt the obvious confounders.
The measure they tracked is worth stating plainly, because it is not simple percent body weight. They asked how much of the regained weight a patient took back off, defined as the drop from the point where the drug was started, divided by how much had been regained since the post-surgery low point. At six months, GLP-1 users had erased 9.6 percent of the regain against 4.3 percent in non-users. At twelve months the gap widened, 14.8 percent versus 8.1 percent. Both differences cleared statistical significance (p equal to 0.005 and 0.017). Gastrointestinal complaints and surgery-related adverse events were no more common in the drug group.
Read carefully, the numbers are modest and the design is thin. The cohort is small once it narrows to people with real weight recurrence: 68 GLP-1 users at six months, 72 at twelve, against roughly twice as many non-users. It is a retrospective look at who happened to start a drug, not a randomized trial. People who began a GLP-1 may have differed from those who did not in ways matching cannot fully erase. The data come from one state. Follow-up stops at a year. And the ratio metric can flatter a result: reclaiming "half the regain" sounds large, but if the regain itself was moderate, the absolute pounds are smaller than the framing implies. The records also do not pin down which agent or dose each patient took.
None of that makes the finding uninteresting. Weight recurrence after bariatric surgery is one of the field's quieter failure modes. It is common enough that surgeons have wrestled for years with what to do about it, and the honest answer has often been a shrug. This is a real-world signal that the drugs now driving the obesity market do something useful in exactly that gap, and that layering them onto a surgical patient did not, in this dataset, add a safety penalty over the year observed.
On peptidemodel, the agents named here map to live cards: semaglutide ↗, tirzepatide ↗ and liraglutide ↗, all working through the GLP-1 receptor ↗, with tirzepatide adding the GIP receptor ↗. What the study does not answer is the one patients will ask first: does the reclaimed weight stay off after the drug stops, or does the surgery-plus-drug stack simply move the same problem one step downstream. A one-year record cannot say. A trial built to follow people past the prescription could.